Want to see GPCR full AI Analyst Report?
Total Valuation
Structure Therapeutics, Inc. Sponsored ADR has a market cap or net worth of $3.89B. The enterprise value is $2.56K.
Market Cap$3.89B
Enterprise Value$2.56K
Share Statistics
Structure Therapeutics, Inc. Sponsored ADR has 71,309,860 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,309,860
Owned by Insiders10.24%
Owned by Institutions45.46%
Financial Efficiency
Structure Therapeutics, Inc. Sponsored ADR’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is -18.88%.
Return on Equity (ROE)-0.09
Return on Assets (ROA)-0.09
Return on Invested Capital (ROIC)-18.88%
Return on Capital Employed (ROCE)-0.19
Revenue Per Employee0.00
Profits Per Employee-606.02K
Employee Count233
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Structure Therapeutics, Inc. Sponsored ADR is ―. Structure Therapeutics, Inc. Sponsored ADR’s PEG ratio is -11.30.
PE Ratio―
PS Ratio0.00
PB Ratio2.72
Price to Fair Value2.72
Price to FCF-18.23
Price to Operating Cash Flow-17.98
PEG Ratio-11.30
Income Statement
In the last 12 months, Structure Therapeutics, Inc. Sponsored ADR had revenue of 0.00 and earned -141.20M in profits. Earnings per share was -2.40.
Revenue0.00
Gross Profit-3.90M
Operating Income-287.57M
Pretax Income-140.69M
Net Income-141.20M
EBITDA-136.79M
Earnings Per Share (EPS)-2.40
Cash Flow
In the last 12 months, operating cash flow was -220.25M and capital expenditures -4.21M, giving a free cash flow of -224.46M billion.
Operating Cash Flow-220.25M
Free Cash Flow-224.46M
Free Cash Flow per Share-3.15
Dividends & Yields
Structure Therapeutics, Inc. Sponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change173.10%
50-Day Moving Average48.79
200-Day Moving Average53.18
Relative Strength Index (RSI)62.10
Average Volume (3m)749.96K
Important Dates
Structure Therapeutics, Inc. Sponsored ADR upcoming earnings date is Nov 18, 2026, After Close (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date―
Financial Position
Structure Therapeutics, Inc. Sponsored ADR as a current ratio of 24.81, with Debt / Equity ratio of 0.46%
Current Ratio24.81
Quick Ratio24.81
Debt to Market Cap<0.01
Net Debt to EBITDA5.80
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Structure Therapeutics, Inc. Sponsored ADR has paid 515.00K in taxes.
Income Tax515.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Structure Therapeutics, Inc. Sponsored ADR EV to EBITDA ratio is -24.30, with an EV/FCF ratio of -14.72.
EV to Sales0.00
EV to EBITDA-24.30
EV to Free Cash Flow-14.72
EV to Operating Cash Flow-14.96
Balance Sheet
Structure Therapeutics, Inc. Sponsored ADR has $1.34B in cash and marketable securities with $6.23M in debt, giving a net cash position of $1.34B billion.
Cash & Marketable Securities$1.34B
Total Debt$6.23M
Net Cash$1.34B
Net Cash Per Share$18.74
Tangible Book Value Per Share$25.62
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Structure Therapeutics, Inc. Sponsored ADR is $109.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$109.33
Price Target Upside122.58% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast―
EPS Growth Forecast1.47%